A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Trial details
- Registry ID
- NCT05848011
- Phase
- Phase 2
The FDA approved docetaxel (Taxotere®) on 14 May 1996.
Drug identity checked against registry records
Also recorded as Taxotere®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerNCT05848011 | MacroGenics | Phase 2 | Completed | 2026-02-19Actual |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 | RVMD | Phase 3 | Recruiting | 2027-12-01Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1996-05-14Day | docetaxel | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020449", "applicant_as_listed_by_fda": "SANOFI AVENTIS US", "brand_names": ["TAXOTERE"], "active_ingredients": ["DOCETAXEL"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19960514", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |